Crossmark

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s13058-018-1040-9

Published Online: 2018-09-04

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Buus, Richard https://orcid.org/0000-0002-3386-3465
Yeo, Belinda

Brentnall, Adam R.

Klintman, Marie

Cheang, Maggie Chon U.

Khabra, Komel

Sestak, Ivana

Gao, Qiong

Cuzick, Jack

Dowsett, Mitch
Funding

Funding for this research was provided by:

Breast Cancer Now

Cancer Research UK (C569/A16891, C569/A10404, C569/A10404)

NIHR RM/ICR Biomedical Research Centre

Skåne County Council’s Research and Development Foundation

Governmental Funding of Clinical Research within the National Health Service (ALFSKANE-350191)

Swedish Breast Cancer Association

Fru Berta Kamprads Stiftelse

The Inger Persson Research Foundation
License Information

Text and Data Mining valid from 2018-09-04
More Information

Article History

Received: 6 December 2017

Accepted: 8 August 2018

First Online: 4 September 2018

Ethics approval and consent to participate

: The TransATAC study was approved by the South-East London Research Ethics Committee, and all patients gave informed consent. The POLAR study was approved by the RMH Research Ethics Committee (CCR: 4122) and the ethics committee of Lund University Hospital (LU 240-01), and all patients gave informed consent.

: Not applicable.

: MCUC reports patents, royalties, other intellectual property: PAM50 patent. The other authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.